<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928499</url>
  </required_header>
  <id_info>
    <org_study_id>2009-6736</org_study_id>
    <nct_id>NCT00928499</nct_id>
  </id_info>
  <brief_title>Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy</brief_title>
  <official_title>Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sacral Nerve Stimulation (SNS) delivers non-painful, mild electrical pulses to the sacral&#xD;
      nerves to modulate the reflexes that influence the bladder, sphincter, and pelvic floor to&#xD;
      improve or restore normal voiding function. Sacral nerve stimulation is indicated for&#xD;
      refractory voiding dysfunction including urinary urgency/frequency, urinary urge&#xD;
      incontinence, and nonobstructive urinary retention. Since its introduction, SNS has undergone&#xD;
      significant improvements in design and application so that implantation is now a minimally&#xD;
      invasive procedure under local and intravenous (IV) sedation. However, despite the progress&#xD;
      made in advancing this therapy to a minimally invasive procedure, there are neither data nor&#xD;
      guidelines on ideal program settings. The purpose of this study is to evaluate the&#xD;
      programming parameter of cyclic versus continuous stimulation on efficacy of the therapy. If&#xD;
      the therapy is equally efficacious at both settings, the cyclic setting has the advantage of&#xD;
      resulting in a longer battery life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The components of SNS include a quadripolar lead wire that is placed adjacent to a sacral&#xD;
      nerve root (typically S3), and an implantable pulse generator (IPG) that the lead wire is&#xD;
      attached to. The IPG provides the electrical impulse and has several parameters that are&#xD;
      amenable to adjustment including rate, strength and length of stimulation. Additionally, the&#xD;
      stimulation can be programmed to be continuous or cyclic. If the therapy is equally&#xD;
      efficacious at both settings, the cyclic setting has the advantage of resulting in a longer&#xD;
      battery life. This would prolong the time interval between IPG replacements which would&#xD;
      reduce the number of times a patient is exposed to a surgical procedure and may have a&#xD;
      substantial impact on reducing cost to the healthcare system.&#xD;
&#xD;
      Participants will be randomized into one of two groups: either cyclic stimulation or&#xD;
      continuous stimulation after IPG placement and will continue with this setting for four&#xD;
      weeks. Subjects will return to the office 4 weeks post-op. They will complete a 3-day&#xD;
      consecutive voiding diary just prior to their study visit. The subject will then undergo&#xD;
      reprogramming to change the stimulation to the alternate pattern (from cyclic to continuous&#xD;
      or vice versa as appropriate) keeping all other parameters the same. Subjects will be asked&#xD;
      to return to the office 4 weeks after being switched to the alternate setting. She will&#xD;
      complete a 3-day consecutive voiding diary just prior to the visit. The subject will also be&#xD;
      asked their preference of mode of stimulation and the reason for their choice. After this&#xD;
      visit, the participant will be switched to the mode of stimulation that is most efficacious&#xD;
      for her.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Micturitions in 24 Hours</measure>
    <time_frame>After 4 weeks of stimulation a 3-day consecutive voiding diary was completed</time_frame>
    <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Urge Incontinence Episodes in 24 Hours</measure>
    <time_frame>After 4 weeks of stimulation a 3-day consecutive voiding diary was completed</time_frame>
    <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Interstim - continuous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continuous stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interstim - cyclic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cyclic stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interstim (SNS)</intervention_name>
    <description>Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
    <arm_group_label>Interstim - continuous</arm_group_label>
    <arm_group_label>Interstim - cyclic</arm_group_label>
    <other_name>Sacral nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  You are eligible to participate in this study if you have the diagnosis of&#xD;
             urge/frequency or urge incontinence and have undergone a successful Interstim trial&#xD;
             and are planning on proceeding with IPG placement.&#xD;
&#xD;
          -  All subjects must have had a minimum of a 50% improvement of one or more of the&#xD;
             parameters being measured on the voiding diary to be considered a candidate for&#xD;
             implant.&#xD;
&#xD;
          -  Eligibility criteria also include non-pregnant women over the age of 18 who are able&#xD;
             to provide informed consent and are willing to accept randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  You are not eligible to participate in this study if:&#xD;
&#xD;
               -  you are under 18 years of age;&#xD;
&#xD;
               -  pregnant or planning to become pregnant;&#xD;
&#xD;
               -  have underlying neurological disease;&#xD;
&#xD;
               -  stress incontinence;&#xD;
&#xD;
               -  unable to read English;&#xD;
&#xD;
               -  inability to complete the voiding diary; and&#xD;
&#xD;
               -  inability to complete the follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Noblett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCI Women's Healthcare</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>July 23, 2013</results_first_submitted>
  <results_first_submitted_qc>September 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Karen Noblett</investigator_full_name>
    <investigator_title>Division Director</investigator_title>
  </responsible_party>
  <keyword>urge/frequency</keyword>
  <keyword>urge incontinence</keyword>
  <keyword>Interstim</keyword>
  <keyword>after success Interstim planning IPG placement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Medical clinic over the course of 2 years</recruitment_details>
      <pre_assignment_details>No participants were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuous Stimulation First, Then Cyclic Stimulation</title>
          <description>Continuous stimulation first, then cyclic stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
        <group group_id="P2">
          <title>Cyclic Stimulation First, Then Continuous Stimulation</title>
          <description>Cyclic stimulation first, then continuous stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interstim - Continuous Stimulation First, Then Cyclic Stimulation</title>
          <description>Continuous stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
        <group group_id="B2">
          <title>Interstim - Cyclic Stimulation First, Then Continuous Stimulation</title>
          <description>Cyclic stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="12.3"/>
                    <measurement group_id="B2" value="63.4" spread="10.8"/>
                    <measurement group_id="B3" value="64.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Micturitions in 24 Hours</title>
        <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
        <time_frame>After 4 weeks of stimulation a 3-day consecutive voiding diary was completed</time_frame>
        <population>Data was insufficient to be analyzed and therefore no resulting data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Interstim - Continuous, Then Cyclic</title>
            <description>Continuous stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
          </group>
          <group group_id="O2">
            <title>Interstim - Cyclic, Then Continuous</title>
            <description>Cyclic stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Micturitions in 24 Hours</title>
          <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
          <population>Data was insufficient to be analyzed and therefore no resulting data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Urge Incontinence Episodes in 24 Hours</title>
        <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
        <time_frame>After 4 weeks of stimulation a 3-day consecutive voiding diary was completed</time_frame>
        <population>Data was insufficient to be analyzed and therefore no resulting data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Interstim - Continuous, Then Cyclic</title>
            <description>Continuous stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
          </group>
          <group group_id="O2">
            <title>Interstim - Cyclic, Then Continuous</title>
            <description>Cyclic stimulation&#xD;
Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urge Incontinence Episodes in 24 Hours</title>
          <description>Collected in the 3 day voiding diary depending on their primary diagnosis</description>
          <population>Data was insufficient to be analyzed and therefore no resulting data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Interstim - Continuous, Then Cyclic</title>
          <description>Continuous stimulation first, then cyclic stimulation Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
        <group group_id="E2">
          <title>Interstim - Cyclic, Then Continuous</title>
          <description>Cyclic stimulation first, then continuous stimulation Interstim (SNS) : Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Noblett, MD</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>714-456-8564</phone>
      <email>knoblett@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

